Rizk, Dana V.

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 90

Iptacopan in IgA Nephropathy — Final 24-Month Data

Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesComplement system in diseases

Cited by 34

The expanding role of biomarkers in the management of IgA nephropathy

Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 6

Genome-wide studies define genetic mechanisms of IgA vasculitis

Liu, L., Zhu, L., Monteiro-Martins, S., Griffin, A., Vlahos, L. J., Fujita, M., Taylor, A. D., Berrouet, C., Zanoni, F., Marasa, M., et al. (2026) · Nature Communications

Vasculitis and related conditionsRenal Diseases and Glomerulopathies

Cited by 1

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 1